Sign in

CIK 0001314102

  • Non-accelerated filer
  • Smaller reporting company

EyePoint, Inc.

Sign in to watch
Ticker
EYPT
Exchange
Nasdaq
Industry
Laboratory Analytical Instruments
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
262774444
Phone
+1 617-926-5000
Business address
480 PLEASANT STREET, SUITE C400, WATERTOWN, MA, 02472
Former names
EyePoint Pharmaceuticals, Inc., pSivida Corp., pSivida LTD
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2019-06-21 Mazzo David J Director Exercise or conversion · Deferred Stock Units −8,333 0
2019-06-21 Peterson Kristine Director Exercise or conversion +6,667 6,667
2019-06-21 Peterson Kristine Director Exercise or conversion · Deferred Stock Units −6,667 0
2019-06-21 Godshall Douglas Evan Director Exercise or conversion +6,667 36,167
2019-06-21 Godshall Douglas Evan Director Exercise or conversion · Deferred Stock Units −6,667 0
2019-06-21 Duker Jay S. Director Exercise or conversion +6,667 44,167
2019-06-21 Duker Jay S. Director Exercise or conversion · Deferred Stock Units −6,667 0
2019-06-14 Lurker Nancy President & CEO Exercise or conversion +45,000 285,200
2019-06-14 Lurker Nancy President & CEO Exercise or conversion · Restricted Stock Units −45,000 90,000
2019-06-14 Ross Leonard S Exercise or conversion +8,280 87,732
2019-06-14 Ross Leonard S Shares withheld for taxes −2,394 $1.53 $4K 85,338
2019-06-14 Ross Leonard S Exercise or conversion · Restricted Stock Units −8,280 16,560
2019-06-14 Paggiarino Dario A. Chief Medical Officer Exercise or conversion +14,200 42,612
2019-06-14 Paggiarino Dario A. Chief Medical Officer Shares withheld for taxes −4,175 $1.53 $6K 38,437
2019-06-14 Paggiarino Dario A. Chief Medical Officer Exercise or conversion · Restricted Stock Units −14,200 28,400
2019-06-10 Jones David Scott SVP & Chief Commercial Officer Grant or award · Stock Options (Right to buy) +350,000 350,000
2019-05-13 Landis John B. Director Purchase +40,000 $1.74 $70K 40,000
2019-04-12 Duker Jay S. Director Exercise or conversion +20,000 $1.77 $35K 37,500
2019-04-12 Duker Jay S. Director Exercise or conversion · Stock Option (Right to Buy) −20,000 0
2019-04-01 Duker Jay S. Director Purchase +5,000 $1.89 $9K 17,500

Page 36 of 40 · 795 trades